BACKGROUND: This study evaluated efficacy and safety of pemetrexed in patients with refractory soft tissue sarcoma. METHODS: Patients received pemetrexed intravenously at a dose of 500 mg/m² every 21 days until progression or unacceptable toxicity. The primary endpoint was objective tumor response. RESULTS: Fourty-eight of 53 screened patients were included and received a total of 200 cycles (median 2; range 1-30). Median age was 53 years (range, 20-81). The observed toxicity profile was favorable. NCI-CTC hematologic grade 3/4 toxicity consisted of neutropenia in 13 %, anemia in 15 %, and febrile neutropenia in 4 % of patients of patients, respectively. Non-hematologic CTC grade 3/4 toxicity consisted of elevated ASAT/ALAT in 10 %, hyperglycemia in 6 %, infection with or without neutropenia in 6 %, nausea in 2 % and stomatitis in 2 % of patients. No other grade 3 toxicities and no treatment-related toxic deaths were observed. Overall response as defined by RECIST was 5 %, 16 patients experienced stable disease (40 %). The estimated 3- and 6-months progression-free rates were 33.3 % and 14.6 %, respectively. CONCLUSIONS: In patients with refractory STS, pemetrexed is well tolerated and moderately effective. The confirmed objective response rate in STS is low, however, disease stabilizations are seen in a high proportion of patients (ClinicalTrials.gov NCT00427466).
BACKGROUND: This study evaluated efficacy and safety of pemetrexed in patients with refractory soft tissue sarcoma. METHODS:Patients received pemetrexed intravenously at a dose of 500 mg/m² every 21 days until progression or unacceptable toxicity. The primary endpoint was objective tumor response. RESULTS: Fourty-eight of 53 screened patients were included and received a total of 200 cycles (median 2; range 1-30). Median age was 53 years (range, 20-81). The observed toxicity profile was favorable. NCI-CTC hematologic grade 3/4 toxicity consisted of neutropenia in 13 %, anemia in 15 %, and febrile neutropenia in 4 % of patients of patients, respectively. Non-hematologic CTC grade 3/4 toxicity consisted of elevated ASAT/ALAT in 10 %, hyperglycemia in 6 %, infection with or without neutropenia in 6 %, nausea in 2 % and stomatitis in 2 % of patients. No other grade 3 toxicities and no treatment-related toxic deaths were observed. Overall response as defined by RECIST was 5 %, 16 patients experienced stable disease (40 %). The estimated 3- and 6-months progression-free rates were 33.3 % and 14.6 %, respectively. CONCLUSIONS: In patients with refractory STS, pemetrexed is well tolerated and moderately effective. The confirmed objective response rate in STS is low, however, disease stabilizations are seen in a high proportion of patients (ClinicalTrials.gov NCT00427466).
Authors: Xavier García-Del-Muro; Antonio López-Pousa; Joan Maurel; Javier Martín; Javier Martínez-Trufero; Antonio Casado; Auxiliadora Gómez-España; Joaquín Fra; Josefina Cruz; Andrés Poveda; Andrés Meana; Carlos Pericay; Ricardo Cubedo; Jordi Rubió; Ana De Juan; Nuria Laínez; Juan Antonio Carrasco; Raquel de Andrés; José M Buesa Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: Rashmi Chugh; J Kyle Wathen; Robert G Maki; Robert S Benjamin; Shreyaskumar R Patel; Paul A Meyers; Paul A Myers; Dennis A Priebat; Denise K Reinke; Dafydd G Thomas; Mary L Keohan; Brian L Samuels; Laurence H Baker Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: George D Demetri; Sant P Chawla; Margaret von Mehren; Paul Ritch; Laurence H Baker; Jean Y Blay; Kenneth R Hande; Mary L Keohan; Brian L Samuels; Scott Schuetze; Claudia Lebedinsky; Yusri A Elsayed; Miguel A Izquierdo; Javier Gómez; Youn C Park; Axel Le Cesne Journal: J Clin Oncol Date: 2009-08-03 Impact factor: 44.544
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Robert G Maki; J Kyle Wathen; Shreyaskumar R Patel; Dennis A Priebat; Scott H Okuno; Brian Samuels; Michael Fanucchi; David C Harmon; Scott M Schuetze; Denise Reinke; Peter F Thall; Robert S Benjamin; Laurence H Baker; Martee L Hensley Journal: J Clin Oncol Date: 2007-07-01 Impact factor: 44.544
Authors: J T Hartmann; K Oechsle; J Huober; A Jakob; M Azemar; M Horger; L Kanz; C Bokemeyer Journal: Invest New Drugs Date: 2006-05 Impact factor: 3.651